{"id":14666,"date":"2023-08-28T18:32:00","date_gmt":"2023-08-28T10:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14666"},"modified":"2024-12-03T18:57:20","modified_gmt":"2024-12-03T10:57:20","slug":"henlius-pharmaceutical-expands-licensing-agreement-with-kgbio-for-pd-1-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14666","title":{"rendered":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor"},"content":{"rendered":"\n

Shanghai Henlius Biotech Co., Ltd (HKG: 2696<\/a>) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius’s programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast Asian countries. Under the updated deal, KGbio is now permitted to commercialize the drug in agreed Middle East and North Africa countries and regions, including Bahrain, Egypt, Jordan, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, Morocco, Algeria, and Tunisia, excluding T\u00fcrkiye and Israel. The licensed field includes extensive-stage small cell lung cancer (ES-SCLC) and another indication as per a separate agreement. The updated deal is effective immediately and is valid for 10 years upon the first approval of serplulimab in the new territories, with an option for automatic renewal every five years after expiration. <\/p>\n\n\n\n

Financial Terms and Milestones<\/strong>
KGbio will pay Henlius USD 7 million upfront and up to USD 8 million in future regulatory milestones. The USD 650 million sales milestone payment agreed in 2019 now covers both license deals. Additionally, KGbio is committed to paying royalties based on 15% to 20% of the net sales.<\/p>\n\n\n\n

Serplulimab’s Approvals and Indications<\/strong>
Serplulimab has been approved for the treatment of microsatellite highly unstable (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC), and ES-SCLC. The expansion of the licensing agreement with KGbio signifies Henlius’s commitment to increasing global access to its PD-1 inhibitor, potentially benefiting patients in the Middle East, North Africa, and beyond.<\/a>-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[270,862,2313,2314,18],"class_list":["post-14666","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-henlius-biotech","tag-hkg-2696","tag-kalbe-genexine-biologics","tag-kgbio","tag-pd-1-l1"],"yoast_head":"\nHenlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius's programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast Asian countries. Under the updated deal, KGbio is now permitted to commercialize the drug in agreed Middle East and North Africa countries and regions, including Bahrain, Egypt, Jordan, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, Morocco, Algeria, and Tunisia, excluding T\u00fcrkiye and Israel. The licensed field includes extensive-stage small cell lung cancer (ES-SCLC) and another indication as per a separate agreement. The updated deal is effective immediately and is valid for 10 years upon the first approval of serplulimab in the new territories, with an option for automatic renewal every five years after expiration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14666\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14666\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-28T10:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T10:57:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor\",\"datePublished\":\"2023-08-28T10:32:00+00:00\",\"dateModified\":\"2024-12-03T10:57:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Henlius Biotech\",\"HKG: 2696\",\"Kalbe Genexine Biologics\",\"KGbio\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14666#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14666\",\"name\":\"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-28T10:32:00+00:00\",\"dateModified\":\"2024-12-03T10:57:20+00:00\",\"description\":\"Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius's programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast Asian countries. Under the updated deal, KGbio is now permitted to commercialize the drug in agreed Middle East and North Africa countries and regions, including Bahrain, Egypt, Jordan, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, Morocco, Algeria, and Tunisia, excluding T\u00fcrkiye and Israel. The licensed field includes extensive-stage small cell lung cancer (ES-SCLC) and another indication as per a separate agreement. The updated deal is effective immediately and is valid for 10 years upon the first approval of serplulimab in the new territories, with an option for automatic renewal every five years after expiration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14666\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14666#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor - Insight, China's Pharmaceutical Industry","description":"Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius's programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast Asian countries. Under the updated deal, KGbio is now permitted to commercialize the drug in agreed Middle East and North Africa countries and regions, including Bahrain, Egypt, Jordan, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, Morocco, Algeria, and Tunisia, excluding T\u00fcrkiye and Israel. The licensed field includes extensive-stage small cell lung cancer (ES-SCLC) and another indication as per a separate agreement. The updated deal is effective immediately and is valid for 10 years upon the first approval of serplulimab in the new territories, with an option for automatic renewal every five years after expiration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14666","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14666","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-28T10:32:00+00:00","article_modified_time":"2024-12-03T10:57:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14666#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14666"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor","datePublished":"2023-08-28T10:32:00+00:00","dateModified":"2024-12-03T10:57:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14666"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Henlius Biotech","HKG: 2696","Kalbe Genexine Biologics","KGbio","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14666#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14666","url":"https:\/\/flcube.com\/?p=14666","name":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-28T10:32:00+00:00","dateModified":"2024-12-03T10:57:20+00:00","description":"Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement initially struck with PT Kalbe Genexine Biologics (KGbio) in September 2019 regarding Henlius's programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The Indonesian firm was initially granted rights to develop and commercialize the drug in certain Southeast Asian countries. Under the updated deal, KGbio is now permitted to commercialize the drug in agreed Middle East and North Africa countries and regions, including Bahrain, Egypt, Jordan, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, the United Arab Emirates, Morocco, Algeria, and Tunisia, excluding T\u00fcrkiye and Israel. The licensed field includes extensive-stage small cell lung cancer (ES-SCLC) and another indication as per a separate agreement. The updated deal is effective immediately and is valid for 10 years upon the first approval of serplulimab in the new territories, with an option for automatic renewal every five years after expiration.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14666#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14666"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14666#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14666"}],"version-history":[{"count":5,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14666\/revisions"}],"predecessor-version":[{"id":16461,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14666\/revisions\/16461"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}